We would like to share with you an update on the Section structure of Biomedicines (ISSN: 2227-9059). After careful evaluation and analysis, we have made the decision to merge the Section “Drug Discovery” with the Sections “Drug Delivery”, “Drug Metabolism”, and “Pharmacogenomic and Personalized Medicines” to create a new Section “Drug Discovery, Development and Delivery”, and merge the Section “Biomedical Engineering in Human Health” with the Section “Biomedical Materials” to create a new Section “Biomedical Engineering and Materials”. All published papers and Special Issues as well as Topical Collections of the old Sections will be moved to the new Sections of the journal accordingly.

Moreover, the Sections “Cancer Biology and Therapeutics” and “Neurobiology and Neurologic Disease” will be individually renamed as “Cancer Biology and Oncology” and “Neurobiology and Clinical Neuroscience”. All published papers and Special Issues as well as Topical Collections will remain unchanged.

This decision was based on a comprehensive review of the Section’s substantial development. This strategic initiative aims to make the Section structure clearer allowing readers to better identify the articles, enhance the journal’s transdisciplinary focus, foster collaboration across diverse fields, and elevate the impact of published research.

We extend our heartfelt gratitude to the Editorial Board, MDPI leadership team, and all stakeholders for their invaluable contributions and support throughout this transformative process. Together, we are dedicated to advancing the biomedical field.

Biomedicines Editorial Office